To the Editor:

Infection of host cells by human immunodeficiency virus type 1 (HIV-1) is determined by binding of the viral envelope to the CD4 molecule as well as to a coreceptor such as CCR5 or CXCR4.1 Expression of CCR5 is apparently restricted to certain cell types (ie, lymphocytes, monocyte/macrophages, or CD34+ progenitor cells),2-4 which are susceptible to macrophage (M)-tropic (or R5) strains of HIV-1. Because most primary isolates of HIV-1 use CCR5 to enter cells and levels of CCR5 expression correlate well with the infectability with M-tropic HIV-1 in vitro,2 it is important to delineate the cellular and molecular mechanisms whereby expression of CCR5 is regulated. The present study demonstrates that the transcription factor GATA-1 can upregulate CCR5 promoter activity.

The CCR5 promoter region contains at least three GATA-binding elements (Fig 1A). We have previously identified one of those elements as a GATA-1 binding site4 and have designated it as GATA#1. Characterization of the further upstream region demonstrated another GATA binding site (GATA#2) between −734 and −739 relative to the transcription start site (TSS4; data not shown). Further characterization of the promoter showed that one of the DNase-protected areas (FP-5)4 contains a nonconsensus GATA element (Fig 1B), designated as GATA#3. Therefore, we tested whether transcription factors of GATA family can modulate CCR5 promoter activity in transient expression assays. Plasmid pGL-CCR5(WT) contains the CCR5 promoter region between −770 and +61 relative to the TSS, followed by the luciferase gene, and plasmids pGL-CCR5ΔGATA#1, pGL-CCR5ΔGATA#2, pGL-CCR5ΔGATA#3, and pGL-CCR5ΔGATA#1+2+3 have mutations on these GATA-binding sites individually or in combination (see Fig 1A for mutated nucleotides). The indicated CCR5 promoter-luciferase reporter construct was cotransfected with either a GATA-1 expression vector (pMT-GATA1; kindly provided by S.H. Orkin, Harvard University, Boston, MA5) or its parent plasmid (pMT2T) into PM1 cells (CCR5-positive,2,4 CD4+T-lymphoid cell line) or THP-1 cells (CCR5-positive,4monocytoid cell line). Expression of GATA1, but not GATA-2 or GATA-3 (data not shown), upregulated CCR5 promoter activity up to 15-fold; however, mutation on GATA#1 markedly reduced GATA-1–mediated transactivation of the CCR5 promoter (Fig2). Whereas mutation on GATA#2 or GATA#3 alone had only modest effects on the promoter activity, mutation on all three GATA elements further diminished GATA-1 responsiveness compared with mutation on GATA#1 alone (Fig 2). These results indicate that GATA-1 transcription factor upregulates CCR5 promoter activity through interaction with several GATA elements on the promoter.

Fig. 1.

Identification of GATA elements on the CCR5 promoter region. (A) Map and sequence of the CCR5 promoter region. Location and sequences of three GATA elements (GATA#1, GATA#2, and GATA#3) are shown. The sequence shown for GATA#3 was also used as an oligonucleotide probe (F5) for gel-mobility shift assays (see B). Nuleotides shown in upward arrows indicate mutated nucleotides in plasmids pGL-CCR5▵GATA#1, pGL-CCR5▵GATA#2, pGL-CCR5▵GATA#3, and pGL-CCR5▵GATA#1+2+3. Brackets indicate GATA elements. (B) Identification of GATA#3 as a binding site for GATA-1 by gel mobility shift assays. A radiolabeled oligonucleotide F5 corresponding to FP-5 (a DNase-protected area in footprinting assays4) was incubated with nuclear extracts from PM1 cells. Lanes 1 and 9 represent probe alone. Where indicated, a 50- or 500-fold molar excess of oligonucleotide indicated above the figure was added as a competitor. F5-m has mutation on the GATA element as in plasmid pGL-CCR5▵GATA#3. For GATA or AP1 consensus oligonucleotide, see Moriuchi et al.4 Gel shift disruption experiments (lanes 9 through 14) were performed by adding either control Ab or monoclonal antibodies to either GATA-1, GATA-2, or GATA-3 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), as indicated above the figure. The arrow indicates the GATA-1 complex. NS, nonspecific bands; FP, free probe. The experiments were repeated twice with similar results.

Fig. 1.

Identification of GATA elements on the CCR5 promoter region. (A) Map and sequence of the CCR5 promoter region. Location and sequences of three GATA elements (GATA#1, GATA#2, and GATA#3) are shown. The sequence shown for GATA#3 was also used as an oligonucleotide probe (F5) for gel-mobility shift assays (see B). Nuleotides shown in upward arrows indicate mutated nucleotides in plasmids pGL-CCR5▵GATA#1, pGL-CCR5▵GATA#2, pGL-CCR5▵GATA#3, and pGL-CCR5▵GATA#1+2+3. Brackets indicate GATA elements. (B) Identification of GATA#3 as a binding site for GATA-1 by gel mobility shift assays. A radiolabeled oligonucleotide F5 corresponding to FP-5 (a DNase-protected area in footprinting assays4) was incubated with nuclear extracts from PM1 cells. Lanes 1 and 9 represent probe alone. Where indicated, a 50- or 500-fold molar excess of oligonucleotide indicated above the figure was added as a competitor. F5-m has mutation on the GATA element as in plasmid pGL-CCR5▵GATA#3. For GATA or AP1 consensus oligonucleotide, see Moriuchi et al.4 Gel shift disruption experiments (lanes 9 through 14) were performed by adding either control Ab or monoclonal antibodies to either GATA-1, GATA-2, or GATA-3 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), as indicated above the figure. The arrow indicates the GATA-1 complex. NS, nonspecific bands; FP, free probe. The experiments were repeated twice with similar results.

Close modal
Fig. 2.

GATA-1 upregulates CCR5 promoter activity through interaction with GATA elements on the promoter. Twenty million PM1 cells were transfected with 10 μg of the indicated CCR5 promoter-luciferase construct along with 10 μg of either pMT2T or pMT-GATA-1, and luciferase assays were performed 40 hours after transfection, as described previously.4 Results are reported as means ± SD from four independent experiments. Similar results were obtained for THP-1 cells (data not shown).

Fig. 2.

GATA-1 upregulates CCR5 promoter activity through interaction with GATA elements on the promoter. Twenty million PM1 cells were transfected with 10 μg of the indicated CCR5 promoter-luciferase construct along with 10 μg of either pMT2T or pMT-GATA-1, and luciferase assays were performed 40 hours after transfection, as described previously.4 Results are reported as means ± SD from four independent experiments. Similar results were obtained for THP-1 cells (data not shown).

Close modal

GATA-1 is critical for gene expression in hematopoietic progenitor cells5 or eosinophils,6,7 which have been shown to be infectable with M-tropic HIV-13 8; therefore, GATA-1 may play a role in the regulation of CCR5 expression and thereby in the susceptibility of these cells to infection with M-tropic HIV-1.

1
Doms
 
RW
Peiper
 
SC
Unwelcomed guests with master keys: How HIV uses chemokine receptors for cellular entry.
Virology
235
1997
179
2
Wu
 
L
Paxton
 
WA
Kassam
 
N
Ruffing
 
N
Rottman
 
JB
Sullivan
 
N
Choe
 
H
Sodroski
 
J
Newman
 
W
Koup
 
RA
Mackay
 
CR
CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.
J Exp Med
185
1997
1681
3
Ruiz
 
ME
Cicala
 
C
Arthos
 
J
Kinter
 
A
Cantanzaro
 
AT
Adelsberger
 
J
Holmes
 
KL
Cohen
 
OJ
Fauci
 
AS
Peripheral blood-derived CD34+ progenitor cells: CXC chemokine receptor 4 and CC chemokine receptor 5 expression and infection by HIV.
J Immunol
161
1998
4169
4
Moriuchi
 
H
Moriuchi
 
M
Fauci
 
AS
Cloning and analysis of the promoter region of CCR5, a coreceptor for HIV-1 entry.
J Immunol
159
1997
5441
5
Shivdasani
 
RA
Orkin
 
SH
The transcriptional control of hematopoiesis.
Blood
87
1996
4025
6
Yamaguchi
 
Y
Ackerman
 
SJ
Minegishi
 
N
Taniguchi
 
M
Yamamoto
 
M
Suda
 
T
Mechanisms of transcription in eosinophils: GATA-1, but not GATA-2, transactivates the promoter of the eosinophil granule major basis protein gene.
Blood
91
1998
3447
7
McNagny
 
KM
Sieweke
 
MH
Doderlein
 
G
Graf
 
T
Nerlov
 
C
Regulation of eosinophil-specific gene expression by a C/EBP-Ets complex and GATA-1.
EMBO J
17
1998
3669
8
Freedman
 
AR
Gibson
 
FM
Fleming
 
SC
Spry
 
CJ
Griffin
 
GE
Human immunodeficiency virus infection of eosinophils in human bone marrow cultures.
J Exp Med
174
1991
1661
Sign in via your Institution